

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/069050 A1

(51) International Patent Classification:

A61K 31/137 (2006.01) *A61K 31/49* (2006.01)
A61K 31/138 (2006.01) *A61K 31/517* (2006.01)
A61K 31/36 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4178 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4433 (2006.01) *A61P 25/22* (2006.01)
A61K 31/451 (2006.01) *A61P 25/24* (2006.01)
A61K 31/4525 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/FI2023/050545

(22) International Filing Date:

27 September 2023 (27.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20225853 28 September 2022 (28.09.2022) FI

(71) Applicant: **ORION CORPORATION** [FI/FI]; Orionintie 1, FI-02200 Espoo (FI).

(72) Inventors: **KÄHKÖNEN, Marja**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **ROURU, Juha**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **TAAVITSAINEN, Päivi**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI). **TUUNAINEN, Johanna**; c/o ORION CORPORATION, P.O.Box 65, FI-02101 Espoo (FI).

(74) Agent: **ORION CORPORATION**; Intellectual Property Rights, P.O.Box 65, FI-02101 Espoo (FI).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: TASIPIMIDINE AND CYP2D6 INHIBITOR COMBINATION TREATMENT

(57) Abstract: The invention relates to co-administration a CYP2D6 inhibitor with tasipimidine, or a pharmaceutically acceptable salt thereof, in order to improve the pharmacokinetic profile of tasipimidine by decreasing its clearance and inter-individual variation. The invention also relates to a combination of tasipimidine, or a pharmaceutically acceptable salt thereof, and a CYP2D6 inhibitor, and the use of such a combination for the treatment of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use in the treatment of neuropsychiatric disorders.

WO 2024/069050 A1